Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Alectinib,ALEC2023-US,2023,USA,MDV,350,68,52,48,27.5,62,85,5,15,35,30,20,45,30,15,10,20,35,30,18,7,4,9,3,12,25,38,Cisplatin + Pemetrexed,Carboplatin + Paclitaxel,Vinorelbine + Cisplatin,Pemetrexed,0,0,0,22,45,33,15,45,40,65,2
Alectinib,ALEC2022-JP,2022,Japan,Claim Database,420,72,48,52,24.8,55,78,3,18,32,28,22,50,25,13,12,25,30,25,22,9,5,11,4,10,20,40,Cisplatin + Docetaxel,Carboplatin + Pemetrexed,Docetaxel + Cisplatin,Gemcitabine,0,0,0,25,50,35,20,50,30,70,1.5
Alectinib,ALEC2024-EU,2024,Germany,MDV,280,65,55,45,26.2,48,90,7,20,40,25,15,60,20,10,10,30,40,20,15,6,3,8,2,15,30,35,Carboplatin + Docetaxel,Cisplatin + Gemcitabine,Docetaxel + Carboplatin,Vinorelbine,0,0,0,20,40,30,10,40,50,75,2.5
